STOCK TITAN

Masimo Corporation - MASI STOCK NEWS

Welcome to our dedicated page for Masimo Corporation news (Ticker: MASI), a resource for investors and traders seeking the latest updates and insights on Masimo Corporation stock.

Masimo Corporation (NASDAQ: MASI) is a leading global medical technology company specializing in the development and manufacturing of innovative noninvasive patient monitoring technologies. For over 27 years, Masimo has been at the forefront of medical advancements, offering a wide array of sensors and devices that enhance patient care and safety. Their products are designed to provide healthcare professionals with critical information to improve clinical decision-making.

Masimo's core business is divided into two segments: healthcare and non-healthcare. The healthcare segment is the primary revenue generator, focusing on noninvasive patient monitoring technologies, hospital automation, connectivity solutions, and remote monitoring devices. Their clinically proven products are widely used in hospitals, emergency rooms, and clinical settings around the world.

The non-healthcare segment encompasses the consumer audio business, which includes the development, manufacturing, marketing, and licensing of premium and luxury audio sound products. This segment is known for its advanced audio integration technologies that appeal to audiophiles and general consumers alike.

Masimo's recent achievements include expanding their product portfolio with advanced remote monitoring solutions, partnering with leading healthcare organizations, and pioneering innovative technologies that address unsolvable medical challenges. Financially, the company is robust, showing consistent growth and a strong market presence.

Masimo’s dedication to improving lives is evident in their mission to save, extend, and enhance the quality of life across all demographics. Their innovative spirit attracts individuals who are passionate about making a significant impact in the medical field. As they continue to innovate, Masimo remains committed to providing top-tier products that meet the evolving needs of the healthcare industry.

Rhea-AI Summary
Masimo (MASI) reports strong financial results for Q4 2023 and full-year 2023, with consolidated revenue of $548.9 million and $2,048.1 million, respectively. Non-GAAP net income per diluted share for Q4 was $1.25 and $3.79 for the full year. The company's CEO, Joe Kiani, highlights record contract wins, FDA clearances, and growth in hearables business.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
-
Rhea-AI Summary
Masimo (NASDAQ: MASI) and UCHealth announced a strategic collaboration to enhance patient care through virtual care and telehealth. The partnership aims to improve patient outcomes, reduce care costs, and transform care delivery models. Joe Kiani, Masimo's CEO, and Dr. Richard Zane from UCHealth expressed excitement about combining technological and clinical expertise to innovate healthcare solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.38%
Tags
partnership
-
Rhea-AI Summary
Masimo (MASI) introduces MightySat® Medical, the first FDA-cleared fingertip pulse oximeter for OTC use without a prescription. Powered by Masimo SET® pulse oximetry, it offers accurate readings for medical purposes. The device is now available for purchase on masimo.com and will soon be in retail stores nationwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
none
Rhea-AI Summary
Masimo (NASDAQ: MASI) announces the findings of a study that evaluated the impact of low perfusion on the performance of Masimo SET® pulse oximetry across a variety of skin pigmentations. The study demonstrated that Masimo RD SET® sensors accurately measured oxygen saturation for both Black and White subjects, adding to the body of evidence that Masimo SET® pulse oximetry delivers accurate values across the skin tone range, with no clinically significant difference in accuracy or bias, even in challenging conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
none
-
Rhea-AI Summary
Masimo (NASDAQ: MASI) celebrates the Federal Circuit's decision to lift the temporary stay on the import ban of certain Apple Watch models, reinstating the U.S. International Trade Commission's import ban and cease and desist order on Apple watches infringing Masimo's patented pulse oximetry technology. The CEO, Joe Kiani, emphasizes the importance of upholding American inventors' rights and highlights the superiority of Masimo's pulse oximetry technology over Apple Watch's. Masimo's FDA-cleared W1® health watch is positioned as a more reliable alternative, with proven benefits in medical settings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
none
-
Rhea-AI Summary
Masimo (NASDAQ: MASI) has appointed Bob Chapek, former CEO of The Walt Disney Company, to its Board of Directors. Chapek's successful leadership at Disney during the global COVID-19 pandemic, strategic realignment of media and entertainment divisions, and expansion of streaming services make him a valuable addition to Masimo's growth plans. Masimo's Chairman and CEO, Joe Kiani, expressed excitement about Chapek's role in advancing the company's hospital to home strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.06%
Tags
management
Rhea-AI Summary
Masimo Corporation (MASI) announced preliminary financial results for Q4 and full-year 2023, with consolidated revenue of $541-551 million for Q4 and $2,041-2,051 million for full-year 2023. Full-year 2024 guidance includes consolidated revenue of $2,045-2,165 million, with updated non-GAAP earnings per diluted share of $3.44-3.60.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.55%
Tags
-
Rhea-AI Summary
Masimo (NASDAQ: MASI) receives FDA clearance for Stork™, a baby monitoring system for prescription use with babies 0-18 months. Stork provides continuous monitoring of oxygen saturation, pulse rate, and skin temperature, with alarms, for sick and healthy babies at home. It leverages the same Masimo sensor technology used in hospitals and is now available for prescription use as a medical device for healthy or sick babies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.16%
Tags
-
Rhea-AI Summary
Masimo (NASDAQ: MASI) announces findings from a study on the association of Masimo ORi™ and arterial partial pressure of oxygen in patients undergoing non-cardiac thoracic surgery during one-lung ventilation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
none
Rhea-AI Summary
Masimo (MASI) to participate in Piper Sandler 35th Annual Healthcare Conference on November 29, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
conferences

FAQ

What is the current stock price of Masimo Corporation (MASI)?

The current stock price of Masimo Corporation (MASI) is $161.07 as of November 15, 2024.

What is the market cap of Masimo Corporation (MASI)?

The market cap of Masimo Corporation (MASI) is approximately 8.6B.

What is Masimo Corporation's main business?

Masimo Corporation specializes in developing and manufacturing noninvasive patient monitoring technologies and premium audio products.

How long has Masimo Corporation been in operation?

Masimo has been operational for over 27 years, continually innovating in the medical technology field.

What are the key segments of Masimo's business?

Masimo operates in two key segments: healthcare, which includes patient monitoring technologies, and non-healthcare, which includes premium audio products.

What products does Masimo offer?

Masimo offers noninvasive patient monitoring devices, sensors, remote monitoring solutions, hospital automation products, and luxury audio sound systems.

What makes Masimo's products unique?

Masimo's products are known for their innovative, noninvasive technology that provides accurate patient monitoring and critical information for clinical decision-making.

Who uses Masimo's healthcare products?

Masimo's healthcare products are used by healthcare professionals in hospitals, clinics, emergency rooms, and other medical settings.

What recent achievements has Masimo Corporation accomplished?

Masimo has expanded their product portfolio with advanced remote monitoring solutions and established partnerships with leading healthcare organizations.

What is the financial status of Masimo Corporation?

Masimo Corporation has shown consistent financial growth and maintains a strong market presence.

What is Masimo's mission?

Masimo's mission is to save, extend, and improve lives by developing innovative medical technologies and solutions.

Where can I find the latest news about Masimo Corporation?

The latest news about Masimo Corporation can be found on their official website and trusted financial news sources.

Masimo Corporation

Nasdaq:MASI

MASI Rankings

MASI Stock Data

8.60B
53.18M
8.15%
91.14%
6.7%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
IRVINE